Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Table 1

Baseline characteristics in the 2 cohorts.

Variable	Exon 19 ()	Exon 21 ()
Median age	51 (38–76)	57.55 (35–69)
Gender
Male	19 (57.6%)	10 (68.6%)
Female	14 (33.4%)	12 (31.4%)
ECOG PS
0-1	30 (90.9%)	22 (100%)
2	3 (9.1%)	—
Habits
Ex-smoker	10 (30.3%)	5 (22.7%)
Brain metastasis	5 (33.4%)	5 (22.7%)